Gossamer Bio, Inc. — Q1 2024 Form 10-Q Summary
Business context and reporting period
Gossamer Bio is a clinical-stage biopharmaceutical company focused on developing and commercializing seralutinib for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The filing covers the three months ended March 31, 2024. The financial statements are unaudited and prepared under U.S. GAAP.
The company has not generated product revenue and expects continued operating losses while it develops seralutinib. The Phase 3 PROSERA study in PAH was initiated in the fourth quarter of 2023; management expects topline data in the fourth quarter of 2025 and expects to commence a registrational Phase 3 PH-ILD trial in mid-2025.
Financial condition and key metrics
| Metric | Q1 2024 | Q1 2023 / prior period |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $32.4 million | $37.8 million |
| General and administrative expense | $9.6 million | $10.1 million |
| Total operating expenses | $42.0 million | $47.9 million |
| Net loss | $41.9 million | $49.2 million |
| Net loss per share | $0.19 | $0.52 |
| Net cash used in operating activities | $52.3 million | $53.0 million |
| Cash, cash equivalents and marketable securities | $244.4 million | Not clearly provided for the comparable period |
As of March 31, 2024, cash and cash equivalents were $38.9 million and marketable securities were $205.5 million. Total assets were $259.4 million, compared with $311.9 million at December 31, 2023. Accumulated deficit was $1.254 billion.
Total liabilities were $232.6 million, including $196.8 million of net carrying value for the 5.00% convertible senior notes due 2027 and $9.6 million of current Credit Facility debt. The company also had $2.6 million of current operating lease liabilities. The 2027 Notes had a $200.0 million principal balance and a 5.00% fixed interest rate.
Net cash increased by $6.8 million during the quarter. Investing activities provided $61.7 million, primarily from $147.8 million of marketable-securities maturities, partly offset by $86.1 million of purchases. Financing activities used $2.6 million, primarily for $2.9 million of debt principal repayments.
Material changes versus the prior comparable period
- Research and development expense decreased $5.4 million to $32.4 million. Seralutinib spending increased $11.8 million to $29.7 million, while spending on terminated programs declined $17.2 million to $2.6 million.
- Total operating expenses declined $6.0 million, and net loss improved by $7.2 million.
- Other income, net improved by $1.3 million, primarily due to higher investment accretion and lower interest expense.
- Operating cash usage was broadly unchanged, decreasing from $53.0 million to $52.3 million.
- Weighted-average shares outstanding increased to 225.7 million from 94.9 million, reflecting the company’s substantial equity issuance in 2023 and other share issuances.
- Stock-based compensation declined to $5.8 million from $8.1 million.
Guidance, outlook, risks and unusual items
Management believes existing cash, cash equivalents and marketable securities are sufficient to fund operations for at least the next 12 months from the date the financial statements were available for issuance. This estimate is subject to clinical-development timing, cost and financing risks. The company expects to require additional capital and may raise funds through equity, debt, collaborations, licenses or other arrangements.
On May 3, 2024, after the quarter ended, the company entered into a global collaboration and license agreement with Chiesi for seralutinib. Chiesi agreed to pay Gossamer $160 million as consideration and reimbursement for development costs, with potential regulatory milestones of up to $146 million and sales milestones of up to $180 million. The parties will generally share global development costs, with Gossamer solely responsible for the PROSERA Phase 3 study. U.S. commercial profits and losses will generally be shared equally; Chiesi will have exclusive commercialization rights in the rest of the world and will pay escalating mid-to-high teens royalties on applicable net sales. Chiesi also received an option to purchase Gossamer shares, subject to a 9.9% ownership cap and other conditions.
Also on May 3, 2024, the Credit Facility was terminated, repaid in full and discharged, and the lenders released their security interests. This occurred after the balance-sheet date; the March 31, 2024 balance sheet still reflects $9.6 million of Credit Facility debt.
The seralutinib license agreement with Pulmokine includes up to $48 million of development and regulatory milestones, $45 million of commercial milestones, $190 million of sales milestones and tiered royalties. Gossamer paid a $10 million milestone upon initiation of the Phase 3 seralutinib trial in January 2024.
Principal risks include clinical-trial failure or delay, inability to obtain regulatory approval, manufacturing and enrollment challenges, continued need for capital, potential dilution or unfavorable financing terms, dependence on the Chiesi collaboration, possible termination or underperformance of the collaboration, intellectual-property risks, and uncertainty regarding future milestone and royalty obligations. No material legal proceedings were reported, and management stated that disclosure controls were effective at the reasonable-assurance level.
Important facts for investors to verify
- Verify the terms, accounting treatment and cash-receipt timing of the Chiesi collaboration, including the $160 million payment, milestone eligibility, cost-sharing obligations and equity option.
- Confirm that the Credit Facility was fully repaid and that all related liens and security interests were released on May 3, 2024.
- Monitor cash burn, marketable-securities balances and the company’s projected funding runway as PROSERA and the planned PH-ILD Phase 3 program advance.
- Assess the clinical and regulatory probability of success for seralutinib, including the expected PROSERA topline data timing in late 2025.
- Evaluate dilution exposure from 34.9 million outstanding stock options, 32.5 million warrants, potentially convertible 2027 Notes and the Chiesi equity option.
- Review the 2027 Notes’ $200 million principal balance, conversion conditions and maturity on June 1, 2027.